Filing Flows › Enanta Pharmaceuticals (ENTA) › Q2 FY25
Enanta Pharmaceuticals (ENTA) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed May 14, 2025
Enanta Pharmaceuticals (ENTA) reported revenue of $14.9M for the second quarter fiscal 2025 (Q2 FY25), -12% from a year earlier and -12% from the quarter before. Operating margin was -164.3%, net loss $22.6M (151.7% of revenue).
Enanta Pharmaceuticals, Q2 FY25: revenue $14.9M (-12% year over year), operating margin -164.3%, net loss $22.6M, operating cash flow −$13.5M. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.9M | -12% | -12% |
| Operating profit | −$24.5M | — | — |
| Net earnings | −$22.6M | — | — |
| Operating cash flow | −$13.5M | — | — |
What changed
Revenue was $14.9M in Q2 FY25, down 12% year over year and down 12% from the previous quarter.
Operating costs exceeded revenue by $24.5M, an operating margin of -164.3%. Total costs fell 21% while revenue fell 12%. The quarter ended with a net loss of $22.6M, wider than the previous quarter's $22.3M loss.
Operating cash flow was −$13.5M. Non-cash charges added back $1.2M of depreciation and amortization and $4.7M of share-based compensation. Working capital and other items added $3.3M. Capital expenditures of $2.5M exceeded it, leaving free cash flow of −$16.0M.
Questions
What was Enanta Pharmaceuticals' revenue in the second quarter fiscal 2025?
Enanta Pharmaceuticals (ENTA) reported revenue of $14.9M for the second quarter fiscal 2025 (Q2 FY25), -12% from a year earlier and -12% from the quarter before.
Was Enanta Pharmaceuticals profitable in the second quarter fiscal 2025?
Operating loss was $24.5M (-164.3% of revenue) and net loss $22.6M.